Sanofi Consumer Healthcare India Ltd

Sanofi Consumer Healthcare India Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 22 June 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 31 July 2026, providing investors with the most up-to-date perspective on the company’s performance and outlook.

Sanofi Consumer Healthcare India Limited posted a net profit of ₹68.80 crores for Q1 FY27 (June 2026), marking a modest sequential increase of 1.47% from ₹67.80 crores in Q4 FY26 and a robust year-on-year surge of 13.35% from ₹60.70 crores in Q1 FY26. The ₹10,931-crore pharmaceuticals company, trading at ₹4,746.25, has delivered mixed signals with revenue growth tempered by margin compression, even as the stock gained 0.65% following the results announcement.

Sanofi Consumer Healthcare India Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 22 June 2026. While the rating was revised on that date, the analysis and financial metrics presented here reflect the stock's current position as of 20 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Sanofi Consumer Healthcare India Ltd has experienced a subtle shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. Despite mixed signals from key indicators such as MACD, RSI, and moving averages, the stock’s recent price action and technical parameters suggest cautious optimism for investors navigating the Pharmaceuticals & Biotechnology sector.

Sanofi Consumer Healthcare India Ltd has experienced a notable shift in its technical momentum, transitioning from a mildly bullish stance to a sideways trend. Recent technical indicators including MACD, RSI, Bollinger Bands, and moving averages reveal a complex picture of price action and momentum, signalling caution for investors amid mixed signals in the Pharmaceuticals & Biotechnology sector.

Sanofi Consumer Healthcare India Ltd has experienced a subtle shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. Despite mixed signals from key indicators such as MACD, RSI, and moving averages, the stock’s recent price action and technical parameters suggest cautious optimism for investors navigating the Pharmaceuticals & Biotechnology sector.

Sanofi Consumer Healthcare India Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 22 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Sanofi Consumer Healthcare India Ltd has experienced a notable shift in its technical momentum, transitioning from a mildly bullish stance to a sideways trend. This change is underscored by mixed signals from key technical indicators such as MACD, RSI, Bollinger Bands, and moving averages, reflecting a cautious market sentiment despite the company’s stable fundamentals.

Sanofi Consumer Healthcare India Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 22 June 2026. While the rating was revised on that date, the analysis and financial metrics presented here reflect the company’s current position as of 28 June 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Sanofi Consumer Healthcare India Ltd has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish stance as of late June 2026. Despite a slight decline in its share price, the stock’s technical indicators present a nuanced picture, reflecting both cautious optimism and areas of concern for investors navigating the Pharmaceuticals & Biotechnology sector.

Sanofi Consumer Healthcare India Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. Despite a modest day change of 0.27%, the stock’s technical indicators reveal a complex picture of strength and caution, reflecting evolving investor sentiment in the Pharmaceuticals & Biotechnology sector.

Sanofi Consumer Healthcare India Ltd has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish stance as of late June 2026. Despite a day decline of 2.24%, the stock’s technical indicators present a nuanced picture, reflecting both resilience and caution in the pharmaceuticals and biotechnology sector.

Sanofi Consumer Healthcare India Ltd has seen its investment rating upgraded from Hold to Buy, reflecting improved technical indicators, robust financial trends, and a strong quality profile despite valuation concerns. The upgrade, effective from 16 June 2026, highlights the company’s positive momentum in the pharmaceuticals sector amid a challenging market backdrop.

Sanofi Consumer Healthcare India Ltd has demonstrated a notable shift in price momentum, transitioning from a mildly bullish to a bullish technical trend. This change is underpinned by a series of positive signals across key technical indicators, including MACD, moving averages, and on-balance volume, suggesting renewed investor confidence in the pharmaceutical sector stock.

Sanofi Consumer Healthcare India Ltd has experienced a notable shift in its technical parameters, moving from a mildly bearish to a mildly bullish trend. Despite a slight dip in the daily price, key indicators such as the MACD and moving averages signal improving momentum, suggesting cautious optimism for investors in the Pharmaceuticals & Biotechnology sector.

The 50-day moving average has crossed above the 200-day moving average for Sanofi Consumer Healthcare India Ltd, signalling a golden cross on 8 Jun 2026. Yet, the stock declined 1.29% on the same day, and monthly technical indicators remain inconclusive. This juxtaposition of signals calls for a detailed examination of the broader technical and fundamental context.